Posted Nov 9, 2017 Thanks MS News Today for highlighting our MS program. We are very excited to move this program forward with the support of National Multiple Sclerosis Society!
Posted Oct 27, 2017 We are pleased to announce that we recently received funding from the National Multiple Sclerosis Society to evaluate LBT-3627 for MS! Way to go team... now the real work begins. Hope we can make a real difference in patients lives!
Posted Aug 14, 2017 Been a busy summer here at Longevity Biotech. Check out this recent commentary in The Lancet regarding autoimmunity and Parkinson's Disease from our friends at University of Nebraska Medical Center - UNMC (17)30276-4/abstract Bottom line is that there is still more work to be done, contact us for more information!
Posted Apr 25, 2017 Looking for a new exciting, challenging job where you have an impact? Well, we are hiring...
Posted Mar 24, 2017 Congrats to the University of Nebraska Medical Center - UNMC team. We look forward to continuing our collaboration and developing the next generation drug candidates.
Posted Mar 23, 2017 Huge congrats to our friends at University of Nebraska Medical Center - UNMC on the publication of their Parkinson's disease clinical trial! Exciting times indeed!
Posted Feb 13, 2017 Longevity Biotech is pleased to be included as one of the emerging new classes of therapeutics for the most challenging drug targets. Contact us for more information on how Hybridtides© can help your therapeutics program...
Posted Feb 7, 2017 We are pleased to share the press release that went out this morning about our Parkinson's disease program and our collaborations with University of Nebraska Medical Center - UNMC and The Michael J. Fox Foundation for Parkinson's Research. Great work team!
Posted Dec 28, 2016 Longevity Biotech will be attending the upcoming #RESI17 conference on Tuesday Jan 10th 2017. We still have a few meeting times available during #JPM17 week - please contact us to learn more about our neuroscience & diabetes programs and how we are attempting to treat these diseases by targeting gut receptors with our Hybridtide platform technology!